Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: Systematic reviewers of randomized controlled trials

Asian Journal of Andrology

Volumn 15, Issue 4, 2013, Pages 471-482

  Ma, Chun Ho ^a   Lin, Wai Ling ^a   Lui, Sing Leung ^b   Cai, Xun Yuan ^a   Wong, Vivian Taam ^c   Ziea, Eric ^c   Zhang, Zhang Jin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HOSPITAL AUTHORITY   (Hong Kong)

Author keywords

Benign prostatic hyperplasia (BPH); meta analysis; review; traditional Chinese medicine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHUAN SHAN JIA; CORTEX CINNAMOMI EXTRACT; E SHU; FINASTERIDE; HERBACEOUS AGENT; HUANG BO; HUANG QI; PLACEBO; PLANT EXTRACT; PORIA COCOS EXTRACT; PYGEUM AFRICANUM EXTRACT; REHMANNIA GLUTINOSA EXTRACT; SABAL EXTRACT; SHAN ZHU YU; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; UNCLASSIFIED DRUG; VITAMIN; WANG BU LIU XING; ZE XIE;

ABDOMINAL DISTENSION; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; BIBLIOGRAPHIC DATABASE; CHINESE MEDICINE; CLINICAL PRACTICE; COCHRANE LIBRARY; CONSTIPATION; CORTEX CINNAMOMI; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EJACULATION DISORDER; FATIGUE; FEVER; GASTRITIS; HERBAL MEDICINE; HOARSENESS; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; JADAD SCORE; LIBIDO DISORDER; META ANALYSIS; NAUSEA; NEURALGIA; OUTCOME ASSESSMENT; PORIA COCOS; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PRURITUS; PYGEUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED APPETITE; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; SABAL; SCORING SYSTEM; SCROTAL PAIN; SIDE EFFECT; SKIN INFECTION; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URODYNAMICS;

DRUGS, CHINESE HERBAL; HUMANS; MALE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84880113613     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.173     Document Type: Article

References (48)

1. Wei JT, Calhoun E, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. Washington, DC: NIH Publication; 2007. p43-67.
2. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57.
3. Jacobsen SJ, Guess HA, Panser LA, Girman CJ, Chute CG et al. A population-based study of healthcare-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status among Men. Arch Fam Med 1993; 2: 729-35.
4. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact i. The United States. Arch Intern Med 1995; 155: 477-81.
5. Arrighi HM Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy: The Baltimore Longitudinal Study of Aging. Urology 1991; 38(Suppl 1): 4-8.
6. Norman RW, Nickel JC, Fish D, Pickett SN. 'Prostate-related symptoms' in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994; 74: 542-50.
7. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy i. The community. Lancet 1991; 338: 469-71.
8. Berges RR, Pientka L. Management o. The BPH syndrome in Germany: who is treated and how? Eur Urol 1999; 36: 21-7.
9. Sagnier PP, MacFarlane G, Teillac P, Botto H, Richard F et al. Impact of symptoms of prostatism on level of bother and quality of life of men i. The French community. J Urol 1995; 153: 669-73.
10. Bosch J, Hop WC, Kirkels WJ, Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 622-30.
11. Wolfs G, Knottnerus JA, Janknegt RA. Prevalence and detection of micturition problems among 2,734 elderly men. J Urol 1994; 152: 1467-70.
12. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia usin. The international prostate symptom score. Int J Urol 1997; 4: 40-6.
13. Tsukamoto T, Kumamoto Y, Masumori N, Miyakr H, Rhodes T et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391-5.
14. Lee E, Yoo KY, Kim Y, Shin Y, Lee C. Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 1998; 33: 17-21.
15. Gu FL. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J 2000; 113: 299-302.
16. Wong SY, Woo J, Hong A, Leung JC, Kwok T et al. Risk factors for lower urinary tract symptoms in southern Chinese men. Urology 2006; 68: 1009-14.
17. Litwin MS, Saigal CS. Introduction. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. Washington, DC: NIH Publication. p3-7.
18. Bales GT, Christiano AP, Kirsh EJ, Gerber GS. Phytotherapeutic agents i. The treatment of lower urinary tract symptoms: a demographic analysis of awareness and use a. The University of Chicago. Urology 1999; 54: 86-9.
19. Di Silverio F, Flammia GP, Sciarra A, Caponera M, Mauro M et al. Plant extracts in BPH. Minerva Urol Nefrol. 1993; 45: 143-9.
20. Buck AC. Phytotherapy fo. The prostate. Br J Urol 1996; 78: 325-36.
21. Zhou Z, Zhang XH, Yu PL, Dong BR, Jian ZJ. Current status of diagnosis and treatment for benign prostatic hyperplasia in geriatrics outpatient. Chin J Geriatr 2011; 30: 965-7.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al. Assessin. The quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17: 1-12.
23. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011. Available from HYPERLINK ''http:iiwww.cochranehandbook. org''.
24. Manchikanti L, Ailinani H, Koyyalqunta D, Datta S, Singh V et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011; 14: 91-121.
25. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from HYPERLINK ''http:iiwww.cochranehandbook. org''.
26. Xu ZM, Chen XY, Yang CJ, Yang ZW. Chinese medicine ''Shui zhu dan'' for 33 cases of benign prostatic hyperplasia treatment. J Tradit Chin Med 2011; 52: 1054-5.
27. Sengupta G, Hazra A, Kundu A, Ghosh A. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin i. The treatment of benign prostatic hyperplasia in men aged .50 years: a double-blind, doubledummy, randomized controlled trial. Clin Thers 2011; 33: 1943-52.
28. Gao Z, Lun LJ, Shao KQ, Shen JW, Li Q et al. Clinical observation on Qian Lie Xin capsule plus tamsulosin hydrochloride sustained release capsules i. The treatment of benign prostatic hyperplasia with Shi Re Yu Zu syndrome. J TCM Univ Hunan 2011; 31: 17-20.
29. Zhang ZZ. Treatment of 36 cases of benign prostatic hyperplasia by Wan Yang Hua Yu decoction. Chin J Exp Tradit Med Form 2010; 16: 256-7.
30. Hu JH, Yuan YF, Yuan B, He JQ. Effect of Qian Long Tong capsule o. The quality of life o. The benign prostatic hyperplasia patients. Mod J Integrat Tradit Chin West Med 2010; 19: 4680-1.
31. Noguchi M, Kakuma T, Tomiyasu K, Kurita Y, Kukihara H et al. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. Asian J Androl 2008; 10: 651-8.
32. Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K et al. Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. Asian J Androl 2008; 10: 777-85.
33. Zegarra L, Vaisberg A, Loza C, Aguirre RL, Campos M et al. Double-blind randomized placebo-controlled study of Bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia. Int Braz J Urol 2007; 33: 493-500; discussion 501.
34. Wen JY, Lu M, Zhou WZ, Wei XD, Wang Y et al. Treatment of 20 cases of benign prostatic hyperplasia by Tong Qiao Jian. Chin Med Shan Xi 2006; 27: 290-1.
35. Zhang FR. Clinical trial of Li Zhi soft capsule for benign prostatic hyerplasia. Chin J Clin Pharmacol Ther 2004; 9: 1424-7.
36. Zhang YD, Lu ZJ, Zhang P, Huang SG. cases observation o. The efficacy of Yishen zhuyu decoction for benign prostatic hyperplasia treatment. J Nanjing Tradit Chin Med Univ (Nat Sci) 2001; 17: 216-7.
37. China, M.o.H.o. Clinical Research Guidelines of New Chinese Herbal Medicine. Beijing: Ministry of Health o. The People's Republic of China.
38. Sun ZX, Ni LY, Huang J. Observation o. The efficacy o. The adjuvant use of Chinese medicine and Tamsulosin fo. The treatment of benign prostatic hyperplasia and related lower urinary tract symptoms. Shandong J Tradit Chin Med 2009; 28: 22-3.
39. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD et al. Understanding ZHENG in traditional Chinese medicine i. The context of neuro-endocrine-immune network. Iet Syst Biol 2007; 1: 51-60.
40. Benign prostatic hyperplasia. In: Li YQ, Chen HF, Cui XJ, Ai RD, He QH et al, editors. Surgery of Chinese Medicine. Beijing: Chinese Medicine Press. p293-6.
41. Yang X, Ding CF, Ni WD, Yang ZZ. Clinical study of Long shu tong for benign prostatic hyperplasia treatment. Jiangxi J Tradit Chin Med 2009; 40: 28-9.
42. Yuan ZZ. Study of efficacy and mechanism of JinGuiShenQiWan on BPH rats. In Internal Medicine of Chinese Medicine (Andrology). Chengdu: Chengdu University of Chinese Medicine; 2002; 12: 7-8.
43. Wei G. Review o. The pharmacological and clinical studies of Huangqi. Shanxi J Tradit Chin Med 2011; 27: 52-4.
44. Hua ZH. Effects of Radix Astragali on blood glucose concentration and rheology of rat with diabetes mellitus. J Shantou Univ Med Coll 2005; 18: 96-8.
45. Kang HT. Book of Ingredient and Pharmacology of Common Chinese Medicine. Beijing: China Medical Science Press; 1994.
46. Liang SQ. Experimental study o. The antithrombotic effect of Ehong injection. China J Chin Mater Med 1988; 15: 48.
47. Lao AN, Min SS. In:Basic Research of Common Chinese Medicine. Beijing: Frontiers in China; 2002. p80-112.
48. Zang ZP, Jun WZ. Study o. The pharmacology and clinical application of Cortex Phellodendri. Gansu Med J 2010; 29: 329-31.